BRAF and embryonal neoplasm: Leveraging our expression data set of 11 PLAGL1- and PLAGL2-amplified tumor samples and 279 samples from other CNS tumor and normal tissue types (HGGs with H3 G34R/V or K27M mutation and GBM_pedRTK1 or 2 (n = 76), PA with BRAF fusion (n = 25), PXA (n = 25), normal brain tissue (n = 36), embryonal tumors such as ATRT, ETMR, or medulloblastomas (n = 117)), we first compared gene expression of the PLAGL-amplified tumors to our subset of embryonal tumors.